April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Xiuning Le: Presented Dato-DXd with Osimertinib in EGFR-Refractory NSCLC Patients at ELCC25
Mar 29, 2025, 19:01

Xiuning Le: Presented Dato-DXd with Osimertinib in EGFR-Refractory NSCLC Patients at ELCC25

Xiuning Le, Associate Professor at MD Anderson Cancer Center, shared a post on X:

“A very successful ELCC25 I presented Dato-DXd (4mg/kg vs 6mg/kg) with osimertinib in EGFR refractory NSCLC patients, from ORCHARD trial. mPFS 11.7 mon and ORR 36% in Dato-DXd 6mg/kg cohort.

Improving upon what we have and explore new combinations. ”

Xiuning Le: Presented Dato-DXd with Osimertinib in EGFR-Refractory NSCLC Patients at ELCC25

More posts featuring ELCC25.